Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Lodelinsart – page 96

1 315 clinical trials in Lodelinsart, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Lodelinsart at a glance
1 315
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 315 trials in Lodelinsart

Open in trial search

Study on Batoclimab for Patients with Thyroid Eye Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab
  • Sponsor:Immunovant Sciences GmbH

Study on the Effectiveness and Safety of Ranibizumab for Patients with Wet Age-Related Macular Degeneration Using a 36-Week Refill System

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Ranibizumab
  • Sponsor:F. Hoffmann-La Roche AG

Psoriasis

Not recruiting

Study on Bimekizumab and Ustekinumab for Children and Teens with Moderate to Severe Plaque Psoriasis

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Short stature+3

Not recruiting

Study Comparing Somapacitan and Somatropin for Growth in Children with Short Stature Due to Small for Gestational Age, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Somapacitan
  • Sponsor:Novo Nordisk A/S

Glioblastoma multiforme+1

Not recruiting

Study on Early Temozolomide Treatment for Adults with Glioblastoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:Centre Oscar Lambret

Study Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Plasma cell myeloma

Not recruiting

Study Comparing Idecabtagene Vicleucel and Lenalidomide Maintenance Therapy for Adults with Newly Diagnosed Multiple Myeloma After Stem Cell Transplant

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Celgene Corp.

Dermatitis atopic

Not recruiting

Study on Dose Flexibility of Upadacitinib for Adults with Moderate to Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Study on the Effectiveness and Safety of Odronextamab Compared to Standard Treatment in Adults with Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study of Dostarlimab and Drug Combination for Patients with Untreated Resectable Colon Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on the Safety and Effects of Fenfluramine in Infants Aged 1 to Less Than 2 Years with Dravet Syndrome

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Fenfluramine Hydrochloride
  • Sponsor:UCB Biosciences Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.